BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21760593)

  • 41. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells.
    de Jonge-Peeters SD; van der Weide K; Kuipers F; Sluiter WJ; de Vries EG; Vellenga E
    Ann Hematol; 2009 Jun; 88(6):573-80. PubMed ID: 19002460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.
    Deneberg S; Grövdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Döhner K; Paul C; Ekström TJ; Hellström-Lindberg E; Lehmann S
    Leukemia; 2010 May; 24(5):932-41. PubMed ID: 20237504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
    Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
    Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low expression of miR-204 is associated with expression of CD34 and poor performance status in denovo AML.
    Abdelhafiz AS; Elsayed GM; Saber MM; Gameel A; Hamdy N
    Int J Lab Hematol; 2020 Jun; 42(3):263-269. PubMed ID: 32048789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications.
    Won EJ; Kim HR; Park RY; Choi SY; Shin JH; Suh SP; Ryang DW; Szardenings M; Shin MG
    BMC Cancer; 2015 Apr; 15():217. PubMed ID: 25881148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels.
    Hatfield KJ; Hovland R; Øyan AM; Kalland KH; Ryningen A; Gjertsen BT; Bruserud Ø
    Leukemia; 2008 Feb; 22(2):287-93. PubMed ID: 17943167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Tan L; Nagata Y; Takemura T; Asahina A; Yokota D; Yagyu T; Shibata K; Fujisawa S; Ohnishi K
    Mol Carcinog; 2013 Jan; 52(1):57-69. PubMed ID: 22086844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Screening and expression of CD34(+) cell-specific microRNA in acute myelogenous leukemia].
    Wang GP; Zhang SQ; Zhu P; Peng MY; Tan SQ; Yin H; Xu YJ; Chen Y; Chen FP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):541-5. PubMed ID: 22967414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
    Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
    Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
    Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.